Academic Journal
Q1European Journal of Cancer
About European Journal of Cancer
European Journal of Cancer is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 2.692 and an H-index of 263.
Its listed coverage is 1990-2026 and its research categories include Cancer Research (Q1); Oncology (Q1). The 2025 dataset reports 466 documents and 8409 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics.
Recent Research Articles
Latest publications matched automatically by ISSN.
Spectral cytometry-based immune profiling coupled with machine learning identifies circulating Th1-like cells as a blood biomarker for advanced colorectal adenomas
Alejandro G. del Hierro, Sandra Izquierdo, Carolina G. de Castro, Ángel De Prado et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116980Neurocognitive functioning in long-term survivors of glioblastoma, IDH-wildtype and astrocytoma, IDH-mutant, CNS WHO grade 4: A report from EORTC 1419 (ETERNITY)
A. Josephine Drijver, Elke Butterbrod, Caroline Hertler, Sé M. Frances et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116985Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial
Alexander Rühle, Alina Krause, Rachel L. O'Connell, John Simes et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117005Integrating patient preferences into clinical trial outcomes for older adults with cancer: A perspective from the EORTC Older Adult Council and Quality of Life Group
Pierluigi Bonomo, Lissandra Dal Lago, Luigi Lim, Paolo Bossi et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116983A stromal–immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study
Bolin Song, Himanshu Maurya, Tianyi Xia, Naoto Tokuyama et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116979Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial
Maria E. Cabanillas, Naifa L. Busaidy, Mark Zafereo, Priyanka C. Iyer et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117013Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience
Olayode O. Babatunde, Kenneth Seier, Rhoena Desir-Camille, Viswatej Avutu et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117012Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin?
Fabio Conforti, Jacopo Canzian, Benedetta Tinterri, Laura Pala et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117015Incidence and survival of primary bone sarcoma diagnosed in England between 1996 and 2020; An analysis from the National Disease Registration Service
Reuben A. Hastings, Andrew Bacon, Victoria Vinader, Jennifer Gains et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116981Erratum to “Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas” [EJC 40 (2004) 1418]
E. Ryschich, G. Huszty, H.P. Knaebel, M. Hartel et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116923Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe
Sarah Hersey, Haydar Celik, Steven Rosen, Christopher Scott et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117009Response to letter Re: COVID-19 vaccination before immune checkpoint inhibitor initiation and the overall survival of patients with advanced cancer: A cohort study
Pierre-Etienne Heudel, Romain Varnier, Jean-Yves Blay
2026-10 · DOI: 10.1016/j.ejca.2026.117017Development of an age specific EORTC questionnaire to assess the health-related quality of life (HRQOL) of children with cancer aged 8–14 years – a mixed-methods content elicitation phase I & II EORTC QLG study
Chiara Vetrano, Magdalena Balcerek, Maria Rothmund-Grenier, Samantha Sodergren et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117011Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients
Tanja C. van Dijk, Marcel Smid, Debbie G.J. Robbrecht, Khrystany T. Isebia et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116992Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
Roberta Scafetta, Raffaella Troiano, Alessandra Guarino, Carla Gullotta et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117019Immune remodelling and molecular profiling of progressive brain metastases following cranial radiotherapy
Ariane Steindl, Angelika M. Starzer, Erwin Tomasich, Markus Kleinberger et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116988Neoadjuvant chemotherapy reduces regulatory T-cells in cervical cancer
Jelena M. Meek, Iske F. van Luijk, Mark A.J. Gorris, Corneel Coens et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116984Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen
Jean-Yves Blay, Sylvain Lamure, Waisse Waissi, Marie-Pierre Sunyach et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117010Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer
Daniel J. George, Karim Fizazi, Alicia K. Morgans, Hannah D. McManus et al.
2026-10 · DOI: 10.1016/j.ejca.2026.116982Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues
Charles W. Shi, Aagamjit Singh, Atulya A. Khosla, Rohit Thummalapalli et al.
2026-10 · DOI: 10.1016/j.ejca.2026.117004Reviews
Community Reviews
Version History
September 8, 2026 at 12:02 am
September 8, 2026